RIA Advisory Group LLC Purchases New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

RIA Advisory Group LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 16,925 shares of the pharmaceutical company's stock, valued at approximately $6,887,000. Vertex Pharmaceuticals accounts for about 2.0% of RIA Advisory Group LLC's investment portfolio, making the stock its 7th largest holding.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in VRTX. Arlington Trust Co LLC grew its position in shares of Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 33 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $30,000. Baystate Wealth Management LLC grew its position in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company's stock valued at $31,000 after acquiring an additional 25 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at about $25,000. Finally, Cornerstone Planning Group LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $33,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Sanford C. Bernstein cut Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Friday, February 2nd. Oppenheimer reiterated an "outperform" rating and issued a $500.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday. William Blair reiterated an "outperform" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Robert W. Baird cut Vertex Pharmaceuticals from a "neutral" rating to an "underperform" rating and set a $325.00 price objective on the stock. in a report on Wednesday, January 31st. Finally, Truist Financial lifted their price objective on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a "buy" rating in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $429.45.

Vertex Pharmaceuticals Trading Up 0.2 %

Shares of VRTX stock traded up $0.80 during trading on Friday, hitting $394.28. 1,342,016 shares of the stock traded hands, compared to its average volume of 1,246,165. The firm has a market capitalization of $101.91 billion, a P/E ratio of 28.39, a price-to-earnings-growth ratio of 1.85 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The firm's fifty day moving average price is $413.60 and its 200-day moving average price is $397.06. Vertex Pharmaceuticals Incorporated has a 52-week low of $316.43 and a 52-week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same quarter in the previous year, the company earned $3.33 earnings per share. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the business's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares of the company's stock, valued at $31,250,727.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the transaction, the executive vice president now owns 74,364 shares in the company, valued at $31,250,727.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Ourania Tatsis sold 354 shares of the business's stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares of the company's stock, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock valued at $5,203,249 over the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.